| Cat.No. | Name | Information |
|---|---|---|
| M8959 | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM. |
| M6101 | Atezolizumab | Atezolizumab (atezolizumab) is a humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 signaling with PD-1 and B7-1 and restores tumor-specific T-cell immunity. However, it does not affect the interaction of PD-L2 with PD-1. Atezolizumab reacts with murine PD-L1 (for human and non-humanized mice). |
| M3813 | Avelumab (MSB0010718C) | Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1 |
| M6100 | Nivolumab | Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice). |
| M5144 | BMS202 | Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity. |
| M6102 | Pembrolizumab | Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). |
| M25080 | Vudalimab | Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation. |
| M25079 | Zeluvalimab | Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer. |
| M25073 | Socazolimab | Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma. |
| M25070 | Pimivalimab | Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor. |
| M25050 | Acasunlimab | Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer. |
| M25046 | Opucolimab | Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody drug conjugates. Opucolimab can be used for the research of advanced solid tumors. |
| M25035 | Ezabenlimab | Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo. |
| M24968 | Manelimab | Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1). |
| M24961 | PD-1/PD-L1-IN-20 | PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases. |
| M24953 | Balstilimab | Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1. |
| M24946 | Pacmilimab | Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity. |
| M24927 | Lodapolimab | Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody. |
| M24916 | Budigalimab | Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function. |
| M24908 | Prolgolimab | Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma. |
| M24888 | Cetrelimab | Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo. |
| M24881 | Atorolimumab | Atorolimumab (P3x22914G4) is a monoclonal antibody used for immunotherapies targeting programmed death-1 (PD-1). |
| M24818 | Gilvetmab | Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
